Slingshot members are tracking this event:

Ipsen and its Partner Exelixis Receive Positive CHMP Opinion for Cabometyx (Cabozantinib) for the Treatment of Advanced RCC in Adults Following Prior VEGF-Targeted Therapy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks



Additional Information

Additional Relevant Details
  • CHMP recommends approval of Cabometyx™ (cabozantinib) for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy based on the results of a large, randomized Phase 3 trial, METEOR
  • Cabometyx™ (cabozantinib) is the first and only multi-kinase inhibitor with established clinical benefits demonstrated for all three key efficacy endpoints: overall survival (OS), progression-free survival (PFS) and objective response rate (ORR)
  • Cabometyx™ (cabozantinib) significantly improved overall survival across all evaluated patient subgroups
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 22, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cabometyx, Cabozantinib, Rcc, Vegf-targeted Therapy, Chmp